Michael S. Samuel, M.D.

Michael S. Samuel, M.D.

520 East 70th Street Starr Pavilion, 3rd Floor , New York, 10021 (646) 962-2727 Website

Opening hours (11 Nov - 17 Nov)

  • This week| Next week

  • Monday

    closed
  • Tuesday

    closed
  • Wednesday

    closed
  • Thursday

    closed
  • Friday

    closed
  • Saturday

    closed
  • Sunday

    closed

Late night shopping

Late night shopping unknown

Late night shopping

Sunday shopping unknown


Company description

Michael S. Samuel, M.D. is an Assistant Professor of Clinical Medicine at Weill Cornell Medical College and Assistant Attending Physician at New York Presbyterian Hospital. Dr. Samuel took an indirect route to medicine, initially receiving his B.A. in English and Anthropology from Union College. He worked as a treatment counselor for developmentally disabled at-risk youth, and then as a teacher of English as a foreign language in Shenzhen, China. Dr. Samuel subsequently joined the leukemia program at Weill Cornell Medical College as a clinical trials research assistant while completing post-baccalaureate studies at Columbia University. He then received his MD from SUNY Downstate Medical Center College of Medicine in 2009. Thereafter, Dr. Samuel completed both his residency in internal medicine and fellowship in Hematology/Oncology at Montefiore Medical Center. His medical training also included experiences studying acupuncture in Beijing, China, and service as a physician on the medical ward at Kisoro District Hospital in Uganda.Throughout his medical training Dr. Samuel maintained a focus on hematological malignancies and spent his final year of fellowship in the lab of Kira Gritsman, MD, PhD, at Albert Einstein Cancer Center studying the genetic determinants of PI3 kinase pathway dependence in leukemic development. Dr. Samuel now rejoins the Leukemia Program in the division of Hematology/Oncology at Weill Cornell Medical College where he will specialize in the treatment of patients with leukemia, myelodysplasia and myeloproliferative neoplasms, and will be actively involved in the clinical trials research within the program.